Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.
Organon to buy Roivant's dermatology unit for up to $1.2 billion
WEB2 days ago · Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading.
Organon pays up to $1.2B to acquire Dermavant and its steroid …
WEB3 days ago · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in ...
News & Media - Dermavant
WEBJun 25, 2024 · Find the latest news and public announcements from Dermavant Sciences including investor information, pipeline updates and more.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
WEB3 days ago · Resize. By Colin Kellaher. Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on ...
Roivant's Sale Of Dermavant To Organon: Win-Win In Atopic …
WEB1 day ago · From a valuation perspective, ROIV will receive up to $1.2 billion from its Dermavant sale to OGN. However, only $175.0 million is an upfront cash payment, and the rest is contingent on milestones ...
Organon to Acquire Dermavant including its Innovative …
WEB3 days ago · Dermavant has been developing VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older and released positive topline results from its ADORING 1 and 2 ...
Organon to Acquire Dermavant including its Innovative …
WEB2 days ago · JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
Roivant dermatology subsidiary to be acquired by Organon
WEB3 days ago · Dive Brief: Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis.
New Data from Phase 4 Trial of VTAMA® (tapinarof) Cream, 1 ... - Dermavant
WEBOct 16, 2023 · On May 24, 2022, Dermavant announced the FDA approved VTAMA ® (tapinarof) cream, 1% for the treatment of adult plaque psoriasis. The approval made VTAMA cream the first non-steroidal topical novel chemical entity launched for psoriasis in the U.S. in more than 25 years.